Implementing and Sustaining Early Cancer Diagnosis Initiatives in Canada: An Exploratory Qualitative Study.
cancer diagnosis
early cancer diagnosis initiatives
evaluation
health services research
implementation
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
30 10 2021
30 10 2021
Historique:
received:
06
10
2021
revised:
24
10
2021
accepted:
27
10
2021
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
24
3
2022
Statut:
epublish
Résumé
The interval between suspected cancer and diagnosis for symptomatic patients is often fragmented, leading to diagnosis delays and increased patient stress. We conducted an exploratory qualitative study to explore barriers and facilitators to implementing and sustaining current initiatives across Canada that optimize early cancer diagnosis, with particular relevance for symptomatic patients. The national study included a document review and key informant interviews with purposefully recruited participants. Data were analyzed by two researchers using descriptive statistics and thematic analysis. Twenty-two participants from eight provinces participated in key informant interviews and reported on 17 early cancer diagnosis initiatives. Most initiatives (88%) were in early phases of implementation. Two patient-facing and eight provider/organization barriers to implementation (e.g., lack of stakeholder buy-in and limited resources) and five facilitators for implementation and sustainability were identified. Opportunities to improve early cancer diagnosis initiatives included building relationships with stakeholders, co-creating initiatives, developing initiatives for Indigenous and underserved populations, optimizing efficiency and sustainability, and standardizing metrics to evaluate impact. Early cancer diagnosis initiatives in Canada are in early implementation phases. Lack of stakeholder buy-in and limited resources pose a challenge to sustainability. We present opportunities for funders and policymakers to optimize the use and potential impact of early cancer diagnosis initiatives.
Sections du résumé
BACKGROUND
The interval between suspected cancer and diagnosis for symptomatic patients is often fragmented, leading to diagnosis delays and increased patient stress. We conducted an exploratory qualitative study to explore barriers and facilitators to implementing and sustaining current initiatives across Canada that optimize early cancer diagnosis, with particular relevance for symptomatic patients.
METHODS
The national study included a document review and key informant interviews with purposefully recruited participants. Data were analyzed by two researchers using descriptive statistics and thematic analysis.
RESULTS
Twenty-two participants from eight provinces participated in key informant interviews and reported on 17 early cancer diagnosis initiatives. Most initiatives (88%) were in early phases of implementation. Two patient-facing and eight provider/organization barriers to implementation (e.g., lack of stakeholder buy-in and limited resources) and five facilitators for implementation and sustainability were identified. Opportunities to improve early cancer diagnosis initiatives included building relationships with stakeholders, co-creating initiatives, developing initiatives for Indigenous and underserved populations, optimizing efficiency and sustainability, and standardizing metrics to evaluate impact.
CONCLUSION
Early cancer diagnosis initiatives in Canada are in early implementation phases. Lack of stakeholder buy-in and limited resources pose a challenge to sustainability. We present opportunities for funders and policymakers to optimize the use and potential impact of early cancer diagnosis initiatives.
Identifiants
pubmed: 34898549
pii: curroncol28060369
doi: 10.3390/curroncol28060369
pmc: PMC8628805
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4341-4356Subventions
Organisme : CIHR
Pays : Canada
Références
Br J Gen Pract. 2018 Mar;68(668):e211-e224
pubmed: 29440017
Curr Oncol. 2012 Apr;19(2):70-7
pubmed: 22514493
J Natl Cancer Inst Monogr. 2010;2010(40):11-7
pubmed: 20386049
J R Coll Physicians Edinb. 2015;45(3):201-5
pubmed: 26517098
CMAJ Open. 2018 Jun 7;6(2):E227-E234
pubmed: 29880658
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):145-151
pubmed: 27965294
Implement Sci. 2012 Apr 24;7:37
pubmed: 22530986
Eur J Cancer Care (Engl). 2016 Mar;25(2):219-21
pubmed: 26918685
Lancet Oncol. 2021 Jan;22(1):e6
pubmed: 33341123
JCO Glob Oncol. 2020 Feb;6:92-98
pubmed: 32031447
J Med Screen. 2021 Jun;28(2):100-107
pubmed: 33241760
BMC Cancer. 2019 Jan 8;19(1):25
pubmed: 30621616
CMAJ. 2018 Mar 19;190(11):E320-E326
pubmed: 29555862
BMC Cancer. 2015 Dec 28;15:1017
pubmed: 26711742
Ann Thorac Med. 2021 Jan-Mar;16(1):81-101
pubmed: 33680129
BMC Health Serv Res. 2017 Jun 28;17(1):448
pubmed: 28659143
Br J Cancer. 2012 Mar 27;106(7):1262-7
pubmed: 22415239
Lancet Oncol. 2017 May;18(5):577
pubmed: 28343979